Bellicum Pharmaceuticals in $55 million Series C financing

Posted on 28 August 2014


Bellicum Pharmaceuticals today announced the successful completion of a $55M Series C financing.

The financing will be used to expand the clinical evaluation of Bellicum’s stem cell transplant, chimeric antigen receptor T cell and cancer vaccine product candidates in a variety of blood and solid tumor cancers, and in nonmalignant genetic diseases.

Eleven new investors participated in the financing round, including funds managed by RA Capital Management, LLC, Perceptive Advisors, LLC, Jennison Associates LLC , Sabby Capital, LLC, Ridgeback Capital Management, venBio Select, Redmile Group, LLC, AJU IB Investment and others.

All of the Company’s major current investors, including AVG Ventures and Remeditex Ventures, participated in the financing.

The Series C financing brings the total capital raised since inception to $107 million.

For further deal information visit Current Agreements (subscription required)


Read: more on financing deals in pharma, biotech, life science partnering deal news, insights and glossary

Report: Finding Biopharma and Collaboration Partners

Related reports:  Entire Current Partnering reports catalog

View: Top 50 pharma – overview of top 50 pharmaceutical companies by revenue – partnering activity, deal news, partnering dealtalk

View: Current Partnering Insight Financing Scorecard – view top life science financing deals by value

View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making

View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity

Signup: Current Partnering Dealmakers Update – weekly newsletter providing the latest life science industry deal news, deal making trends, partnering events – sign up now

Signup: Current Agreements Deals Review – monthly newsletter – reviewing the previous month’s life science deal making – partnering, M&A and financing – sign up now

Print Friendly, PDF & Email

Leave a Reply